

DAFTAR PUSTAKA

- Abdel-Bari, A., 2011. Once versus individualized multiple daily dosing of Once versus individualized multiple daily dosing of linezolid. *Saudi Pharmaceutical Journal*, Volume 19, pp. 9-17.
- Alisjahbana, B. et al., 2006. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. *The International Journal of Tuberculosis and Lung Disease*, Volume 10, pp. 696-700.
- Alisjahbana, B. et al., 2007. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clinical Infectious Diseases*, Volume 45, pp. 424-435.
- Alomar, M. J., 2014. Factors affecting the development of adverse drug reactions. *Saudi Pharmaceutical Journal*, Volume 22, pp. 83-94.
- Astari, P., 2019. Tuberkulosis Intraokular. *Nusantara Medical Science Journal*.
- Badri, M. et al., 2001. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. *International Journal of Tuberculosis and Lung Disease*, Volume 5, pp. 225-232.
- Barbachyn, M. R. & Ford, C. W., 2010. Oxazolidinone Structure-Activity Relationship Leading to Linezolid. *Angewandte Chemie*.
- BC Cancer, 2020. Hematology and Associated Laboratory Tests.
- Bernstein, W. B. & Richard F Trotta, J. T. R. J. A. T. a. A. J. B., 2003. Mechanisms for Linezolid-Induced Anemia and Trombocytopenia. *The Annals of Pharmacotherapy* , Volume 37, pp. 517-520.
- Behbehani, R., 2007. Clinical approach to optik neuropathies. *Clinical Ophthalmology*, Volume 3, pp. 233-246.
- BPOM, 2012. *Pedoman Moniroring Efek Samping Obat Bagi Tenaga Kesehatan*. Jakarta: s.n.

- Busti, A. J., 2015. The Mechanism for Linezolid (Zyvox) Induced Thrombocytopenia. *EBM Consult*.
- Carey, P. J., 2003. Drug-Induced Myelosuppression. *Practical drug safety*, pp. 691-703.
- Chang, Y. P., 2012. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. *BMC Nephrology*, Volume 13, pp. 1-7.
- Collins, K. R., nones-Mateu, M. E. Q., Toossi, Z. & Arts, E. J., 2002. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. *AIDS Review*, Volume 4, pp. 165-176.
- Conradie, F., Diacon, A. H., Ngubane, N. & Howell, P., 2020. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *The New England Journal of Medicine*, Volume 382, pp. 893-902.
- Corbett, E. L., Watt, C. J. & Walker, N., 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Archives of Internal Medicine*, Volume 163, pp. 1009-1021.
- Dannenbergh, A. M. Jr., 2006. Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model. Washington, DC: *ASM Press*
- Dinkes Surabaya, 2016. *Profil Kesehatan Kota Surabaya Tahun 2016*. Surabaya: Dinkes Kota.
- Dryden, M. S., 2011. Linezolid Pharmacokinetics and pharmacodynamics in clinical treatment. *Journal of Antimicrobial Chemotherapy*, Volume 6.
- Elkington, P., Tebruegge, M., and Mansour, S., 2016. Tuberculosis: an infection-initiated autoimmune disease? *Trends Immunol.* 37, pp 815–818.
- Escombe AR, Moore DA, Gilman RH, et al, 2008. The infectiousness of tuberculosis patients coinfecting with HIV. *PLoS Med* 5(9), e188.
- Espinal, M. A., N, E., ez, P. & ez, J. B., 2000. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. *The Lancet*, Volume 355, pp. 275-280.

- Falzon, D. & Harausz, E., 2017. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. *European Respiratory Journal*, Volume 3, pp. 160-230.
- Farihatun, S. & Bungsu, P., 2018. Determinant Factors of Drop Out Among Multi Drug Resistance Tuberculosis Patients at Jakarta Province 2011-2015. *Indonesia Journal of Tropical and Infectious Disease*, Volume 7.
- Fatmawati, U. & Kusmiati, T., 2017. Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016. *Jurnal Respirasi*, Volume 3, pp. 35-41.
- Ferry, T. et al., 2018. Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug Resistant Staphylococcus epidermidis Prosthetic-Joint Infection. *Open Forum Infectious Diseases*.
- Fox, K. A., et al., 2018. Platelets regulate pulmonary inflammation and tissue destruction in tuberculosis. *Am. J. Respir. Crit. Care Med.* 198, pp 245–255.
- Gerson, S. L. et al., 2002. Hematologic Effects of Linezolid: Summary of Clinical Experience. *American Society for Microbiology*, p. 2723–2726.
- Grange, J.M., 2014. Chapter 3: *Mycobacterium tuberculosis* – The Organism. In: Davies, P.D.O., Gordon, S.B., Davies, G., (Ed). *Clinical Tuberculosis 5th edition*. New York: CRC Press p. 39-50..
- Hanai, Y. et al., 2016. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. *Journal of Infection and Chemotherapy*, Volume 22, pp. 536-542.
- Hidayatullah, A. P., 2016. Indeks kejadian tuberkulosisi resisten obat pada penderita tuberkulosis di kabupaten gresik jawa timur.
- Hunter R. L., 2016. Tuberculosis as a three-act play: a new paradigm for the pathogenesis of pulmonary tuberculosis. *Tuberculosis* 97, pp 8–17.

- Irianti T., Kuswandi, Yasin N.M., Kusumaningtyas R.A., 2016. *Buku Anti-tuberkulosis*. Yogyakarta: UGM Press.
- Johnson, R., Streicher, E.M., Louw, G.E., Warren, R.M., van Helden, P.D., and Victor, T.C., 2007. Drug Resistance in Mycobacterium tuberculosis. *Curr. Issues Mol. Biol.* 8p.97–112.
- Kılıç, E. K. et al., 2019. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. *The Journal of Infection in Developing Countries*, Volume 10, pp. 886-891.
- Kemenkes, 2014. *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta: Depkes RI.
- Kemenkes, 2016. Panduan Pelayanan Tuberkulosis Resisten Obat untuk Fasilitas Pelayanan Kesehatan, Kementerian Kesehatan Republik Indonesia
- Kemenkes, 2019. Panduan Pelayanan Tuberkulosis Resisten Obat untuk Fasilitas Pelayanan Kesehatan, Kementerian Kesehatan Republik Indonesia dan Gerakan Masyarakat Hidup Sehat: Edisi 3 April 2019.
- Lammermann, T., et al., 2013. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. *Nature* 498, pp 371–375.
- Lee, M. et al., 2012. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. *New England Journal*, Volume 16, pp. 1508-1518.
- Locke, J. B. et al., 2010. Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing the cfrMethyltransferase Gene or Ribosomal Mutations. *American Society for Microbiology*, pp. 5337-5343.
- Maartens, G. & Benson, C. A., 2015. Linezolid for Treating Tuberculosis: A Delicate Balancing Act. *El Sevier*, pp. 1568-1569.
- McEvoy G.K., 2006. American Hospital Formulary Service. *AHFS Drug Information*. American Society of Health-System Pharmacists, Bethesda, MD., pp. 568.
- Meissner, H. et al., 2003. Hematologic effects of linezolid in young children. *pediatric infectious disease journal*, Volume 9, pp. 186-192.

- Meyboom, Lindquist, M. & Egberts, A., 2000. An ABC Drug related problem. *Drug Safety*, Volume 22, pp. 415-423.
- Micromedex, 2018. *Linezolid drug Interaction*, Chicago: IBM corporation.
- Migliori, G. et al., 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. *Eur Respir Journal*, Volume 34, pp. 387-383.
- Millard, J. et al., 2018. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta analysis and Monte Carlo simulation. *Journal of Antimicrobial Chemotherapy*, pp. 1-8.
- Milliron, B., Henry, T. S., Veeraraghavan, S., and Little, B. P. (2015). Bronchiectasis: mechanisms and imaging clues of associated common and uncommon diseases. *Radiographics* 35, pp 1011–1030.
- Muller, B., Borrell, S., Rose, G., and Gagneux, S., 2012. The Heterogeneous Evolution of Multidrug-Resistant Mycobacterium Tuberculosis. *Trend in Genetics-1013* p. 1-10.
- Namdar, R., Lauzardo, M. & Peloquin, C., 2016. Tuberculosis. In: M. A. Chisholm-Burns, et al. eds. *Pharmacotherapy Ptinciples & Practice*. New York: Mc Graw Hill.
- Narasimhan, P., Wood, J., Macintrye, C. R. & Mathai, D., 2013. Risk Factors for Tuberculosis. *Hindawi Publishing Corp*, Volume 11.
- Nasraway, S. A. et al., 2004. Linezolid Does Not Increase the Risk of Thrombocytopenia in Patients with Nosocomial Pneumonia : Comparative Analysis of Linezolid and Vancomycin Use. *Clinical Infectious Diseases*, Volume 37, pp. 1609-1616.
- Natsumoto, B., Yokota, K., Omata, F. & Furukawa, K., 2014. Risk factors for linezolid-associated thrombocytopenia in adult patients. *Springerlink Journal*, pp. 1007-1012.
- Nawas, A., 2010. Penatalaksanaan TB MDR dan Strategi DOTS Plus dalam Jurnal Tuberculosis Indonesia Vol. 7. Jakarta: *Perkumpulan Pemberantasan Tuberculosis Indonesia (PPTI)*. pp 1-5.

- Nishijo, N. et al., 2017. Mechanism Underlying Linezolid-induced Thrombocytopenia in a Chronic Kidney Failure Mouse Model. *Journal of Pharmacology & Pharmacotherapeutics*, Volume 1, pp. 8-13.
- Niwa, T. et al., 2009. Retrospective Cohort Chart Review Study of Factors Associated With the Development of Thrombocytopenia in Adult Japanese Patients Who Received Intravenous Linezolid Therapy. *Clinical Therapeutics*, Volume 31, pp. 2126-2133.
- Nukui, Y. et al., 2013. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. *Journal of Antimicrobial Chemotherapy*, Volume 68, pp. 2128-2133.
- Oktafia, D., 2017. Analisis Kejadian Efek Samping Obat Rejimen terapi Tuberkulosis Resistan Obat.
- Onnroth, K. L. et al., 2008. Alcohol use as a risk factor for tuberculosis-a systematic review. *BMC Public Health*, Volume 8.
- Pai, M., Mohan, A. & Dheda, K., 2007. Lethal interaction: the colliding epidemics of tobacco and tuberculosis. *Expert Review of Anti-Infective Therapy*, Volume 5, pp. 385-391.
- Pozniak, A., 2018. Clinical manifestations and complications of pulmonary tuberculosis. *UpToDate*.
- Ramachandran, G. & Swaminathan, S., 2015. Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications. *Drug Safety Journal*.
- Rao, N. et al., 2004. Similar hematologic effect of long-term linezolid and vancomycin therapy in a prospective observational study in patient with orthopedic infections. *Clin Infect Dis Journal*, pp. 1058-1064.
- Rodenbur, E. M., Stricker, B. H. & Visser, L. E., 2012. Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions. *British Journal of Clinical Pharmacy*, Volume 74.

- Sakamoto, K. et al., 2013. Mycobacterial trehalose dimycolate reprograms macrophage global gene expression and activates matrix metalloproteinases. *Infect. Immun Journal*, Volume 81, p. 764–776..
- Singh, B., Cocker, D., Ryan, H. & Sloan, D., 2019. Linezolid for drug-resistant pulmonary tuberculosis (Review). *Cochrane Library*.
- Soedarsono, 2018. Initial Implementation of Shorter Regimen for MDR-TB in Dr Soetomo Hospital, Surabaya : The proportion between Eligibility and Ineligibility.
- Takahashi, Y. et al., 2010. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. *Journal of Infectious Diseases*, Volume 17, pp. 382-387.
- Tang, S. et al., 2015. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. *Eur Respir Journal*.
- Tobin, D. M., et al., 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. *Cell* 148, pp 434–446.
- Vinh, D. & Rubinstein, E., 2009. Linezolid: a review of safety and tolerability. *Journal Infect*, Volume 59, pp. 559-574.
- Vriese, A. S. D. et al., 2006. Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. *Clinical Infectious Diseases*, pp. 1111-1117.
- Wang, H., Yu, M. & Ochani, M., 2002. Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation. *Nature*, Volume 421, pp. 384-388.
- WHO, 2010. *Equity, Social Determinants and Public Health Programmes*. Geneva: World Health Organization.
- WHO, 2011. *Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update..* Geneva: World Health Organization.
- WHO, 2016. *Treatment Guidelines for Drug-Resistant Tuberculosis - 2016 update..* Geneva: World Health Organization.

- WHO, 2018. *Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)*. Geneva: World Health Organization.
- WHO, 2019. *Global Tuberculosis Report 2019: Executive Summary*. Geneva: s.n.
- Wiesman, J. F., 2016. *Peripheral Neuropathy : What it is and What you can do to feel better*. Baltimore: Johns Hopkins University Press.
- Willekens, C. et al., 2013. Linezolid induces ring sideroblasts. *Haematologica Journal*, Volume 139, p. 98.
- Yogev, R. et al., 2003. Linezolid for the treatment of complicated skin and skin structure infections in children. *Pediatric Infectious Disease Journal*, pp. 172-177.
- Zhang, X. et al., 2015. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. *Journal of Thoracic Disease*, Volume 4, pp. 603-615